--
Related Articles
Research
Research Alert: CFRA Maintains Buy Opinion On Shares Of Seagate Technology Holdings Plc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our price target from $509 to $811, 29x our CY 27 EPS estimate ($27.95), well above STX's three-year average (~16x), as accelerating AI demand structurally improves HDD industry growth and visibility, with the company reportedly nearly sold out of nearline capacity through CY 27. We lift our FY 26 EPS estimate by $2.01 to $14.92, lift our FY 27 estimate by $5.36 to $24.30, and initiate a FY 28 estimate at $31.20. Q3 results were spectacular, with results and guidance coming in well ahead of expectations on accelerating AI demand. We expect the results also reflect share gains for HDD at the expense of NAND-intensive SSDs given elevated memory prices, which should stick around through 2027. Looking forward, we are impressed by STX's rollout timelines for Mozaic 4+ (expected to contribute a majority of HAMR exabytes by CYE 26) and Mozaic 5+ (50 TB/drive), with shipments slated for late CY 27. We see STX's technological lead continuing to improve in this area, helping boost sales, margins, and cash flow.
$STX
Research
Research Alert: Aercap Holdings Posts Q1 Beat & Raise, Strong Asset Demand And Margin Expansion
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AerCap delivered record Q1 adj. EPS of $5.39, up 46% Y/Y, beating consensus by $1.68, while generating 19% adjusted ROE. Revenues rose 8% Y/Y to $2.24B (+9% above consensus), driven by basic lease rents of $1.68B and robust asset sales of $1.5B generating $291M in gains (+64% Y/Y) at 24% unlevered margins. The company achieved an 87% lease extension rate and executed strong capital deployment with $745M in share repurchases. Management raised full-year 2026 adjusted EPS guidance to ~$14.50 (from a range of $12.00 to $13.00), excluding additional asset sale gains. AerCap added 110 new A320neo aircraft to its order book, with deliveries starting in 2028, positioning the company to capitalize on persistent OEM production constraints. We believe the combination of elevated asset values, premium pricing power, and locked-in delivery slots for fuel-efficient aircraft should drive sustained spread expansion and excess capital generation well beyond 2026. This creates potential for continued double-digit EPS growth.
$AER
US Markets
AbbVie Raises 2026 Outlook Following First-Quarter Beat on Immunology Growth
AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected first-quarter results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs.Per-share adjusted earnings are expected at $14.08 to $14.28 for 2026, up from prior guidance of $13.96 to $14.16. The guidance includes $0.41 in expenses related to acquired in-process research and development and milestone expenses in the first quarter. The current consensus on FactSet is for non-GAAP EPS of $14.12.AbbVie now expects revenue of about $67.3 billion for the current year, an increase of $300 million, Chief Financial Officer Scott Reents said during an earnings call, according to a FactSet transcript. The Street is looking for $67.07 billion.The company's shares rose 0.9% in Wednesday trading. The stock has dropped 13% this year.For the March quarter, the company reported adjusted EPS of $2.65, up from $2.46 a year earlier and ahead of the Wall Street estimate of $2.59. Revenue climbed 12% to $15 billion, surpassing the estimate on FactSet for $14.72 billion."We are off to an excellent start in 2026, with first-quarter results exceeding our expectations," CEO Robert Michael said in a statement. "AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook."Global sales from the immunology portfolio rose 16% to $7.29 billion. Gains of 31% for Skyrizi and 23% for Rinvoq helped counter a 39% drop for Humira. In the neuroscience segment, revenue jumped 26% to $2.89 billion, while oncology portfolio sales eased 0.2% to $1.63 billion.Revenue in the aesthetics portfolio increased 7.6% to $1.19 billion.AbbVie projects adjusted EPS of $3.74 to $3.78 in the current quarter on revenue of $16.7 billion, including a foreign-exchange gain of 0.6%, Reents said on the call. Analysts project non-GAAP EPS of $3.75 on sales of $16.8 billion.Price: $199.39, Change: $+1.70, Percent Change: +0.86%
$ABBV